FIELD: chemistry.
SUBSTANCE: present invention provides a dihydropyridazine-3,5-dione derivative or a pharmaceutically acceptable salt thereof, a prophylactic and / or therapeutic agent for hyperphosphatemia, secondary hyperparathyroidism and chronic renal failure, comprising the compound as an active ingredient.
EFFECT: present enables to solve problems that arise when using phosphorus adsorbents.
18 cl, 45 dwg, 418 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL AGENT CONTAINING INHIBITOR OF SODIUM-DEPENDENT PHOSPHATE CARRIER | 2015 |
|
RU2740008C2 |
| PHARMACEUTICAL PRODUCT CONTAINING INHIBITOR OF SODIUM DEPENDENT PHOSPHATE CARRIER | 2015 |
|
RU2811864C1 |
| NOVEL ISOQUINOLINE DERIVATIVES | 2020 |
|
RU2839897C2 |
| PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | 2021 |
|
RU2840769C1 |
| THERAPEUTICALLY ACTIVE DERIVATIVES OF OXAZOLINE | 2013 |
|
RU2656209C2 |
| N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDE COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | 2015 |
|
RU2821520C2 |
| NEW ANTHELMINTIC QUINOLINE-3-CARBOXAMIDE DERIVATIVES | 2017 |
|
RU2772283C2 |
| NOVEL BICYCLIC DERIVATIVES | 2020 |
|
RU2830113C2 |
| NEW AZAQUINOLINE DERIVATIVES | 2018 |
|
RU2773290C2 |
| HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | 2018 |
|
RU2797822C2 |
Authors
Dates
2018-07-31—Published
2014-03-13—Filed